TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34902047

Group type: EXPERIMENTAL
Intervention: Sepsis originating from the abdomen
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: Sepsis originating from the urinary tract, cardiovascular, and skin infections
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: Sepsis originating from the CNS
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: Comparison of abdominal and pulmonary infections
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: Source of infection
Number of subjects: 2019
Study: 34902265

Group type: EXPERIMENTAL
Intervention: Grazoprevir (GZR) 100 mg/Elbasvir (EBR) 50 mg daily for 12 weeks
Number of subjects: 14
Study: 34902336

Group type: EXPERIMENTAL
Intervention: USPSTF2013 criteria
Number of subjects: 5819

Group type: COMPARATOR
Intervention: PLCOm2012 model (risk threshold of at least 1.70% at 6 years)
Number of subjects: 5819
Study: 34902506

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2375

Group type: EXPERIMENTAL
Intervention: CVD
Number of subjects: 2375
Study: 34902623

Group type: COMPARATOR
Intervention: Accelerated intermittent Theta Burst Stimulation (aiTBS) targeting the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: aiTBS targeting the left DLPFC
Number of subjects: 41
Study: 34902760

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cladribine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alemtuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alemtuzumab and Cladribine
Number of subjects: 0
Study: 34902800

Group type: EXPERIMENTAL
Intervention: Deep sedation with 10 mg/kg/h Propofol and nasal oxygen 0.3 ml/kg/min
Number of subjects: 25
Study: 34902818

Group type: EXPERIMENTAL
Intervention: Psychometric scores at T0 (outbreak), T1 (lockdown), T2 (reopening)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Personality disorders (PDs)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Schizophrenia (SKZ)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Obsessive-compulsive (OC) symptoms
Number of subjects: 166
Study: 34903176

Group type: EXPERIMENTAL
Intervention: Crystalloids (80% balanced solutions)
Number of subjects: 6314

Group type: EXPERIMENTAL
Intervention: Intraoperative colloids
Number of subjects: 6314

Group type: EXPERIMENTAL
Intervention: Low-risk patients undergoing low- or intermediate-risk surgery
Number of subjects: 6314

Group type: EXPERIMENTAL
Intervention: High-risk patients undergoing low- or intermediate-risk surgery
Number of subjects: 6314

Group type: EXPERIMENTAL
Intervention: Low-risk patients undergoing high-risk surgery
Number of subjects: 6314

Group type: EXPERIMENTAL
Intervention: High-risk patients undergoing high-risk surgery
Number of subjects: 6314

Group type: EXPERIMENTAL
Intervention: Advanced fluid monitoring strategies
Number of subjects: 6314
Study: 34903190

Group type: EXPERIMENTAL
Intervention: ≥4 antenatal care visits
Number of subjects: 21223

Group type: COMPARATOR
Intervention: <4 antenatal care visits
Number of subjects: 21223
Study: 34903218

Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 104
Study: 34903251

Group type: EXPERIMENTAL
Intervention: Virtual reality-enhanced personal construct therapy (PCT-VR)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Personal construct therapy (PCT)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 225
Study: 34903452

Group type: EXPERIMENTAL
Intervention: RO4929097 in combination with exemestane
Number of subjects: 15
Study: 34903471

Group type: EXPERIMENTAL
Intervention: Metastasis-directed radiotherapy (MRT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (no MRT)
Number of subjects: 91
Study: 34903545

Group type: EXPERIMENTAL
Intervention: Activity Measure for Post-Acute Care mobility scale
Number of subjects: 211
Study: 34903842

Group type: EXPERIMENTAL
Intervention: CAN04 (1.0-10.0 mg/kg weekly)
Number of subjects: 22
Study: 34904176

Group type: EXPERIMENTAL
Intervention: Modified ILI (requiring only self-reported fever)
Number of subjects: 1040

Group type: COMPARATOR
Intervention: ILI (WHO definition including fever)
Number of subjects: 1040

Group type: COMPARATOR
Intervention: ILI definitions (both modified and WHO)
Number of subjects: 1040

Group type: COMPARATOR
Intervention: ILI
Number of subjects: 1040
Study: 34904191

Group type: EXPERIMENTAL
Intervention: Support vector classifier incorporating fractional anisotropy and mean diffusivity measured in deep white matter, and age at the time of injury.
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Support vector classifier
Number of subjects: 246
Study: 34904813

Group type: EXPERIMENTAL
Intervention: Inhibitors of poly(ADP-ribose) polymerase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other DDR inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATR/CHK1 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ATM/CHK2 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA-PKcs inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polymerase θ inhibitors
Number of subjects: 0
Study: 34904871

Group type: EXPERIMENTAL
Intervention: Joint deep learning model for T1 contrast-enhancing lesion segmentation
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Joint deep learning model for T1 unenhancing lesion segmentation
Number of subjects: 796

Group type: COMPARATOR
Intervention: Individual training for T1 contrast-enhancing lesions
Number of subjects: 796
Study: 34905051

Group type: EXPERIMENTAL
Intervention: Bariatric Surgery (BS)
Number of subjects: 158
Study: 34905086

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) via mesenteric injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) via enteral route
Number of subjects: 20
Study: 34905144

Group type: EXPERIMENTAL
Intervention: Dalbavancin (single-dose 1500 mg IV or two-dose regimen 1000 mg IV on day 1, 500 mg IV on day 8)
Number of subjects: 39
Study: 34905749

Group type: EXPERIMENTAL
Intervention: Decision aids (DAs) used for counseling in the intervention group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care without a DA in the control group
Number of subjects: 66
Study: 34905795

Group type: EXPERIMENTAL
Intervention: Hybrid argon plasma coagulation-assisted endoscopic mucosal resection (hAPC-EMR)
Number of subjects: 40
Study: 34906130

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary education program and Tai Chi exercise (Baduanjin), 4-week program with 2-h weekly talks and 1-h Tai Chi class.
Number of subjects: 112
Study: 34906201

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFAs
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 34906208

Group type: EXPERIMENTAL
Intervention: Pharmacist-guided pre-emptive pharmacogenetic testing to support clinical decision making on antidepressant selection and dosing.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (antidepressant pharmacotherapy selected by the treating physician according to current treatment guidelines without knowledge of PGx test results).
Number of subjects: 0
Study: 34906222

Group type: EXPERIMENTAL
Intervention: DBT Skills Training for Emotional Problem Solving for Adolescents (experimental group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (control group)
Number of subjects: 20
Study: 34906248

Group type: EXPERIMENTAL
Intervention: Agitated local anesthetic solution injected through the catheter with color Doppler ultrasound visualization.
Number of subjects: 83
Study: 34906487

Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 18
Study: 34906544

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 205
Study: 34906697

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34906976

Group type: EXPERIMENTAL
Intervention: Thrombectomy with final angiographic expanded Treatment in Cerebral Infarction score of 2c to 3
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cerebral no-reflow detected by CT/MRI perfusion imaging at 24 hours
Number of subjects: 130
Study: 34906983

Group type: EXPERIMENTAL
Intervention: Usual walking in patients with PD
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Dual-task walking in patients with PD
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual walking in healthy controls
Number of subjects: 206

Group type: COMPARATOR
Intervention: Dual-task walking in healthy controls
Number of subjects: 206
Study: 34907053

Group type: EXPERIMENTAL
Intervention: Autism diagnostic pathways
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial recognition of possible autism; referral and triaging; diagnostic model; providing feedback to parents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working in partnership with families; interagency working; training, service evaluation and development
Number of subjects: 0
Study: 34907057

Group type: EXPERIMENTAL
Intervention: Telemedicine Video-Feedback Intervention (TVFI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Booklet Psychoeducational Intervention
Number of subjects: 0
Study: 34907058

Group type: EXPERIMENTAL
Intervention: Weekly self-reported illness prevalence
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Weekly self-reported illness prevalence by sex
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Time loss due to illness
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Common illness symptoms reported
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Sex differences in reported symptoms
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Illness prevalence by season
Number of subjects: 471
Study: 34907065

Group type: EXPERIMENTAL
Intervention: Stoma closure with application of a non-absorbable mesh in the sublay position
Number of subjects: 68

Group type: COMPARATOR
Intervention: Stoma closure without a mesh
Number of subjects: 68
Study: 34907170

Group type: EXPERIMENTAL
Intervention: BNT162b2 (30 μg, 2 doses, 21 days apart)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 34907192

Group type: EXPERIMENTAL
Intervention: Anti-CCR4 monoclonal antibody mogamulizumab
Number of subjects: 0
Study: 34907216

Group type: EXPERIMENTAL
Intervention: Couple-based machine learning model
Number of subjects: 197
Study: 34907467

Group type: EXPERIMENTAL
Intervention: Combined marker configuration (CMC) model using twelve 1-mm tantalum markers for dynamic radiostereometry analysis (dRSA) at 1-year follow-up.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Hybrid model combining CMC model and theoretic marker positions from computer-assisted models for static radiostereometry analysis (sRSA).
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Static radiostereometry analysis (sRSA) using all markers in the model.
Number of subjects: 2
Study: 34907907

Group type: EXPERIMENTAL
Intervention: Diet low in free sugars
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 29
Study: 34907980

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine administered at study entry and at weeks 8 and 24
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 575
Study: 34908153

Group type: EXPERIMENTAL
Intervention: Child exposure (having regular contact with children under 5 living outside of the subject's household)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Frequent contact with children under 5 living outside of the subject's household
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Child exposure
Number of subjects: 1006
Study: 34908561

Group type: EXPERIMENTAL
Intervention: New-TKA
Number of subjects: 1881

Group type: COMPARATOR
Intervention: Existing-TKA
Number of subjects: 1881
Study: 34909518

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 34909520

Group type: EXPERIMENTAL
Intervention: Personal visits discussing social determinants of health
Number of subjects: 0
Study: 34909528

Group type: EXPERIMENTAL
Intervention: Restrictive policies
Number of subjects: 0
Study: 34909537

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34909566

Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids
Number of subjects: 77
Study: 34909721

Group type: EXPERIMENTAL
Intervention: Topical nitric oxide-releasing SB206 gel
Number of subjects: 707

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 707
Study: 34910118

Group type: EXPERIMENTAL
Intervention: Iron supplementation in OW pregnant women
Number of subjects: 83

Group type: COMPARATOR
Intervention: Iron supplementation in NW pregnant women
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Maternal-fetal iron transfer in OW pregnant women
Number of subjects: 83

Group type: COMPARATOR
Intervention: Maternal-fetal iron transfer in NW pregnant women
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Infants born to OW women
Number of subjects: 83

Group type: COMPARATOR
Intervention: Infants born to NW women
Number of subjects: 83
Study: 34910189

Group type: EXPERIMENTAL
Intervention: SUN + Ch (chocolate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SUN + P (apple puree)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dual isotope method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Free 13C-AA ileal digestibility
Number of subjects: 12
Study: 34910278

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Dual Antiplatelet Therapy (DAPT)
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Event-free survival analysis for death, MACE, and bleeding
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Acute Coronary Syndrome (ACS)
Number of subjects: 1565
Study: 34910295

Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Number of subjects: 212
Study: 34910393

Group type: EXPERIMENTAL
Intervention: Niraparib and bevacizumab maintenance therapy
Number of subjects: 44
Study: 34910540

Group type: EXPERIMENTAL
Intervention: Parameters derived from pretreatment dual-layer spectral-detector CT
Number of subjects: 0
Study: 34910556

Group type: EXPERIMENTAL
Intervention: Venetoclax and azacitidine
Number of subjects: 190
Study: 34910821

Group type: COMPARATOR
Intervention: Psychological interventions
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pharmacological interventions
Number of subjects: 37
Study: 34911163

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 34911359

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once daily for up to 18 months
Number of subjects: 250
Study: 34911463

Group type: EXPERIMENTAL
Intervention: REBOA (Resuscitative endovascular balloon occlusion of the aorta) as adjunct treatment to advanced cardiac life support
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: REBOA
Number of subjects: 5
Study: 34911471

Group type: EXPERIMENTAL
Intervention: Screening for life-time history of epilepsy or seizures using self-reported questionnaire data and diagnostic codes.
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Diagnostic validation through chart review for those who scored positive.
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Overall prevalence of seizure disorders in acute psychiatric inpatients.
Number of subjects: 380
Study: 34911479

Group type: EXPERIMENTAL
Intervention: High physical fitness group (HPF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low physical fitness group (LPF)
Number of subjects: 28
Study: 34911525

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral-sciatic nerve block
Number of subjects: 155

Group type: COMPARATOR
Intervention: Ultrasound-guided ankle block
Number of subjects: 155
Study: 34911667

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg BID, with optional up-titration to a maximum of 15 mg BID
Number of subjects: 66
Study: 34911721

Group type: EXPERIMENTAL
Intervention: Experimental therapy (specifics not provided)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 20
Study: 34911791

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 8406

Group type: COMPARATOR
Intervention: No atrial fibrillation (non-AF)
Number of subjects: 8406
Study: 34911812

Group type: EXPERIMENTAL
Intervention: OA patients with painDETECT scores ≥19 (likely NP component)
Number of subjects: 72

Group type: COMPARATOR
Intervention: OA patients with painDETECT scores ≤12 (without likely NP component)
Number of subjects: 72
Study: 34911817

Group type: EXPERIMENTAL
Intervention: RP-3500, a novel ATR kinase inhibitor, administered orally.
Number of subjects: 0
Study: 34911956

Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate (TM), an orally bioavailable copper chelating agent.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate (TM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AMPK inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss of COX17 (copper chaperone)
Number of subjects: 0
Study: 34911992

Group type: EXPERIMENTAL
Intervention: Asunercept 200 mg/week plus standard RT/TMZ (Cohort 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Asunercept 400 mg/week plus standard RT/TMZ (Cohort 2)
Number of subjects: 10
Study: 34912231

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory and antimicrobial cosupplementations, specific dosages and duration not available
Number of subjects: 0
Study: 34912250

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34912347

Group type: EXPERIMENTAL
Intervention: Monocyte HLA-DR (mHLA-DR) expression measurements on initial and third day after sepsis onset.
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Immunomodulatory treatment (not specified in detail).
Number of subjects: 378
Study: 34912624

Group type: EXPERIMENTAL
Intervention: SIFFT-derived sacroiliac-leveling exercise (SIFFT-E)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pelvic stabilization belt
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined use of SIFFT-E and belt after one month
Number of subjects: 72
Study: 34912839

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34912869

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention for risk-based prevention of heart failure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34913153

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 257
Study: 34913268

Group type: EXPERIMENTAL
Intervention: Telehealth education program conducted by DNP students
Number of subjects: 0
Study: 34913326

Group type: EXPERIMENTAL
Intervention: Prolonged use of CNSDs (≥4 weeks)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Prolonged use of opioids (≥4 weeks)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Prolonged use of CNSDs
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Prolonged use of opioids
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Patients with one or more pain sites
Number of subjects: 246
Study: 34913412

Group type: EXPERIMENTAL
Intervention: Highly similar and competing visual scenes
Number of subjects: 0
Study: 34913584

Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Scales (Vineland-3)
Number of subjects: 22
Study: 34913611

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34913784

Group type: EXPERIMENTAL
Intervention: Liraglutide (with or without exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide combined with exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liraglutide alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study: 34913855

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34914545

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (group B, step-up dosing)
Number of subjects: 230
Study: 34914616

Group type: EXPERIMENTAL
Intervention: Automated SMS text messages aimed at improving the redemption of WIC-approved foods for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated SMS text messages
Number of subjects: 0
Study: 34914658

Group type: EXPERIMENTAL
Intervention: Hyperoxia during Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO)
Number of subjects: 0
Study: 34914727

Group type: EXPERIMENTAL
Intervention: Automated VIA Classifier (AVC)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Visual Inspection with Acetic Acid (VIA)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Histopathological examination
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Participants' and providers' acceptability of AVC technology
Number of subjects: 6000
Study: 34914826

Group type: EXPERIMENTAL
Intervention: Blinatumomab (4 cycles administered every 3 months during the first year after HCT)
Number of subjects: 21
Study: 34914894

Group type: EXPERIMENTAL
Intervention: Conservative management (placenta left in situ)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Cesarean hysterectomy
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 148
Study: 34915057

Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brepocitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withdrawal of ritlecitinib and brepocitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Re-treatment with ritlecitinib and brepocitinib
Number of subjects: 0
Study: 34915264

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No CPAP (Control)
Number of subjects: 97
Study: 34915574

Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg intravenous every 28 days for ≤7 years
Number of subjects: 71
Study: 34915826

Group type: EXPERIMENTAL
Intervention: Web-based cross-sectional survey using the HAD scale
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Web-based cross-sectional survey using the PSS-10 questionnaire
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Web-based cross-sectional survey using the Short Form 12 Questionnaire (SF-12)
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Post-lockdown assessment
Number of subjects: 1565